Pulmatrix Capex To Revenue from 2010 to 2024

PULM Stock  USD 6.64  0.70  9.54%   
Pulmatrix Capex To Revenue yearly trend continues to be very stable with very little volatility. Capex To Revenue is likely to grow to 0.18 this year. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.09262812
Current Value
0.18
Quarterly Volatility
0.18404024
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pulmatrix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pulmatrix's main balance sheet or income statement drivers, such as Interest Expense of 185.2 K, Other Operating Expenses of 16.9 M or Research Development of 10.3 M, as well as many indicators such as Price To Sales Ratio of 0.88, Dividend Yield of 0.1 or PTB Ratio of 0.4. Pulmatrix financial statements analysis is a perfect complement when working with Pulmatrix Valuation or Volatility modules.
  
Check out the analysis of Pulmatrix Correlation against competitors.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.

Latest Pulmatrix's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Pulmatrix over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Pulmatrix's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pulmatrix's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Pretty Stable
   Capex To Revenue   
       Timeline  

Pulmatrix Capex To Revenue Regression Statistics

Arithmetic Mean0.16
Geometric Mean0.06
Coefficient Of Variation116.95
Mean Deviation0.15
Median0.09
Standard Deviation0.18
Sample Variance0.03
Range0.5388
R-Value(0.17)
Mean Square Error0.04
R-Squared0.03
Significance0.54
Slope(0.01)
Total Sum of Squares0.47

Pulmatrix Capex To Revenue History

2024 0.18
2023 0.0926
2022 0.0142
2021 0.0279
2020 0.0222
2019 0.007332
2018 0.12

About Pulmatrix Financial Statements

Pulmatrix investors utilize fundamental indicators, such as Capex To Revenue, to predict how Pulmatrix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capex To Revenue 0.09  0.18 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:
Check out the analysis of Pulmatrix Correlation against competitors.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.64)
Revenue Per Share
3.119
Quarterly Revenue Growth
(0.16)
Return On Assets
(0.30)
Return On Equity
(0.59)
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.